



Ifw

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
1662/60707

Application Number
10/621,623

Filing Date
July 16, 2003

Examiner
To Be Assigned

Art Unit
1614

Invention Title
NOVEL SYNTHESIS OF IRBESARTAN

Inventor(s)
Ben-Zion DOLITZKY et al.

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450 on:

Date: June 9, 2004

Signature: Catherine Edmund

Sir:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies of patents, publications or other information listed on the modified PTO Form No. 1449 are enclosed, except as otherwise indicated.
3. Applicants' attorney certifies that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of information disclosure statement.

Dated:

4/30/04

By:

John B. Starr, Jr.
John B. Starr, Jr. (Reg. No. 44,474)

KENYON & KENYON
One Broadway
New York, New York 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NUMBER 26646



INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	ATTY. DOCKET NO. 1662/60707	SERIAL NO. 10/621,623
	APPLICANT Ben-Zion DOLITZKY et al.	
	FILING DATE July 16, 2003	GROUP 1614

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLAS S	SUBCLAS S	FILING DATE*

* A copy is not enclosed since it was cited in the specification of the present application which was filed after June 30, 2003.

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA- TION	
						YES	NO
	WO 99 38847 A	August 5, 1999	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		LeBourdonnec, B. et al.; Synthesis and Pharmacological Evaluation of New Pyrazolidine-3,5-diones as AT ₁ Angiotensin II Receptor Antagonists, J. Med. Chem., Vol. 43, No. 14, 2000, pp 2685-2697; XP002259509

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	